Anil Khubchandani has been appointed as the Managing Director and CEO of the active pharmaceutical ingredient (API) investment platform of Sekhmet Pharmaventures. Sekhmet Pharmaventures is a pharmaceutical investment platform supported by PAG, a private equity investor focused on the Asia-Pacific region.
PAG has previously invested in two Indian pharmaceutical companies, namely Anjan Drug and Optimus Group, as per reported by VCCircle.
“I am excited by the opportunity to apply my diverse experience, enhance creativity and innovation, build a strong team, and help realize the growth vision aligned to value systems that PAG and its partners have established for this platform,” Khubchandani, an IIT-BHU and IIM Calcutta alumnus said, commenting on his appointment.
Sekhmet Pharmaventures, the Indian subsidiary of Singapore-based Gamot API Pte. Ltd is supported by PAG, a venture capital firm focused on the Asia Pacific region, along with consortium partners CX Partners and Samara Capital. These private equity players have invested in Gamot API and have now extended their investments to Sekhmet Pharmaventures. As of September 2022, Sekhmet Pharmaventures has invested in two Indian API (Active Pharmaceutical Ingredient) companies.
About Sekhmet Pharmaventures Pvt. Ltd.
Sekhmet Pharmaventures Pvt. Ltd. (part of Gamot API Pte Ltd. based in Singapore). Asian private equity major PAG has formed an investment platform called Gamot API Pte. Ltd. based in Singapore, along with Indian private equity firms, CX Partners and Samara Capital, to buy stakes in fast-growing pharma companies. Gamot API is led by PAG as a majority partner. The Indian arm of Gamot API is known as Sekhmet Pharmaventures Pvt. Ltd.